Table 3.
Associations between statin exposure based on solubility and breast cancer incidence in the Nurses’ Health Study, among new initiators of statins 2004–2012.
| No. cases | Age-adjusted HR (95% CI) |
Multivariate** HR (95% CI) |
|||
|---|---|---|---|---|---|
| All invasive cases (n=1,337) | |||||
| Lipophilic statins | |||||
| Never-user of any statin | 849 | 1. | ref | 1. | ref |
| Former users | 76 | 1.1 | (0.84, 1.4) | 1.0 | (0.79, 1.3) |
| Current users | 185 | 1.2 | (1.0, 1.4) | 1.1 | (0.94, 1.3) |
| Hydrophilic statins | |||||
| Never-user of any statin | 849 | 1. | ref | 1. | ref |
| Former users | 90 | 1.1 | (0.89, 1.4) | 1.1 | (0.84, 1.3) |
| Current users | 101 | 1.1 | (0.89, 1.4) | 1.0 | (0.81, 1.3) |
| Invasive ductal carcinoma (n=802) | |||||
| Lipophilic statins | |||||
| Never-user of any statin | 515 | 1. | ref | 1. | ref |
| Former users | 40 | 1.1 | (0.79, 1.5) | 0.99 | (0.71, 1.4) |
| Current users | 94 | 1.1 | (0.90, 1.4) | 1.0 | (0.82, 1.3) |
| Hydrophilic statins | |||||
| Never-user of any statin | 515 | 1. | ref | 1. | ref |
| Former users | 35 | 0.94 | (0.66, 1.4) | 0.87 | (0.60, 1.3) |
| Current users | 63 | 1.1 | (0.87, 1.5) | 1.0 | (0.79, 1.4) |
| Invasive lobular carcinoma (n=123) | |||||
| Lipophilic statins | |||||
| Never-user of any statin | 76 | 1. | ref | (not estimable) | |
| Former users | 6 | 0.91 | (0.39, 2.1) | ||
| Current users | 16 | 1.2 | (0.70, 2.1) | ||
| Hydrophilic statins | |||||
| Never-user of any statin | 76 | 1. | ref | (not estimable) | |
| Former users | 6 | 0.83 | (0.35, 2.0) | ||
| Current users | 9 | 0.99 | (0.49, 2.0) | ||
| ER-positive cases (n=919) | |||||
| Lipophilic statins | |||||
| Never-user of any statin | 581 | 1. | ref | 1. | ref |
| Former users | 45 | 1.0 | (0.75, 1.4) | 0.94 | (0.69, 1.3) |
| Current users | 107 | 1.1 | (0.90, 1.4) | 1.0 | (0.83, 1.3) |
| Hydrophilic statins | |||||
| Never-user of any statin | 581 | 1. | ref | 1. | ref |
| Former users | 44 | 0.95 | (0.69, 1.3) | 0.91 | (0.66, 1.3) |
| Current users | 71 | 1.1 | (0.86, 1.4) | 1.0 | (0.79, 1.3) |
| ER-negative cases (n=168) | |||||
| Lipophilic statins | |||||
| Never-user of any statin | 107 | 1. | ref | 1. | ref |
| Former users | 12 | 1.6 | (0.85, 2.9) | 1.5 | (0.78, 2.7) |
| Current users | 24 | 1.4 | (0.88, 2.2) | 1.3 | (0.83, 2.1) |
| Hydrophilic statins | |||||
| Never-user of any statin | 107 | 1. | ref | 1. | ref |
| Former users | 7 | 0.93 | (0.42, 2.1) | 0.86 | (0.38, 2.0) |
| Current users | 13 | 1.1 | (0.62, 2.0) | 1.0 | (0.56, 1.9) |
| In situ cases (n=210) | |||||
| Lipophilic statins | |||||
| Never-user of any statin | 136 | 1. | ref | (not estimable) | |
| Former users | 9 | 0.98 | (0.49, 2.0) | ||
| Current users | 25 | 1.2 | (0.77, 1.8) | ||
| Hydrophilic statins | |||||
| Never-user of any statin | 136 | 1. | ref | (not estimable) | |
| Former users | 8 | 0.97 | (0.46, 2.1) | ||
| Current users | 14 | 0.99 | (0.56, 1.8) | ||
**
Adjusted for body mass (continuous), first-degree family history of breast cancer (dichotomous), personal history of benign breast disease (dichotomous), parity and age at first birth (design variables: see categories in methods section), age at menarche (<12, 12–13, or 14+), cumulative average ethanol consumption (design variables: see categories in methods section), MHT use (design variables: see categories in methods section), prevalent diabetes, and concomitant use of aspirin, ibuprofen, preventive tamoxifen, beta blockers, calcium channel blockers, ACE inhibitors, and digoxin.